Whitepapers/App Notes/Posters

Application Note: Sensitive quantitation of the ADC ado-trastuzumab emtansine free cytotoxic drug DM1 in serum using MicroLC-MS

Posted: 19 February 2019 | | No comments yet

Antibody-drug conjugates (ADC’s) are targeted cancer therapeutics that deliver a cytotoxic agent, the payload, to the tumour.

For a good understanding of the pharmacokinetics of these drugs, it is important to quantitate not only the antibody, but also the amount of released payload in plasma/serum upon drug administration. ELISA based methods have been used for quantitation, but recently there has been interest in using liquid chromatography- tandem mass spectrometry (LC-MS/MS) methods because of its high selectivity, accuracy, and precision. Especially for Drug Metabolism and Pharmacokinetics (DMPK) studies involving small animals, sensitivity is critical because of the limited volume of sample available. Previously, see Table 1, we have demonstrated improved sensitivity of up to five fold for the quantitation of the ADC Ado-Trastuzumab Emtansine1 and the Antibody Infliximab2 with trap-and elute microflow LC in plasma when compared to using conventional analytical LC-MS/MS. In this presentation we describe the use of Microflow LC for the LC-MS/MS analysis of the payload Emtansine (DM1) of the ADC Ado-trastuzumab Emtansine.











To read this application note in full, please complete the form below. By clicking submit you confirm that you accept our terms and conditions and privacy policy.


*

*

*

*

*

*

*

*

This content is provided to you for free thanks to the kind support of our sponsors: Sciex

Send this to a friend